IRIDEX Delivers Record-Breaking Q4 Performance with Strong Revenue Growth and Cost Optimization
IRIDEX, a leading provider of ophthalmic diagnostic imaging products, has announced its fourth quarter and full year results for 2025. The company's financial performance has exceeded expectations, marking a successful transformation and setting the stage for sustainable profitability.
In a conference call held on March 26, 2026, Patrick Mercer, IRIDEX's Chief Executive Officer, highlighted the company's achievements in streamlining operations, reducing costs, and driving revenue growth. For the full year 2025, IRIDEX grew revenue by 8% compared to the prior year, with operating expenses reduced by 22%. This strategic shift has enabled the company to deliver positive adjusted EBITDA for the first time in its recent history.
The fourth quarter of 2025 saw a remarkable increase in revenue, with growth of 16% marking the strongest quarterly performance of the year. Mercer attributed this success to several factors, including the company's efforts to right-size its operations and reduce costs. IRIDEX has made significant progress in relocating general and administrative functions out of California, which is expected to generate approximately $165,000 in quarterly savings beginning in Q1 2026.
The relocation of the company's headquarters later in 2026 will further reduce fixed costs by around $600,000 on an annualized basis. Additionally, IRIDEX is in active discussions with contract manufacturers as part of a multi-year initiative to transition production away from its Mountain View facilities and toward lower-cost third-party manufacturing. This move is expected to incrementally lower the cost of goods as the year progresses.
Looking ahead, Mercer emphasized the importance of these strategic initiatives in driving long-term sustainability and profitability for IRIDEX. The company's focus on leveraging its installed base of Cyclo G6 systems and promoting higher procedural utilization has also shown positive results, particularly in the glaucoma business. With a solid foundation established, IRIDEX is poised to capitalize on emerging opportunities and continue its growth trajectory.
As the company looks to 2026 and beyond, investors and analysts are taking note of IRIDEX's progress towards sustainable profitability. The company's ability to balance revenue growth with cost optimization has created a compelling narrative for future success. With its commercial results showing resilience in the face of industry challenges, IRIDEX is emerging as a leader in the ophthalmic diagnostic imaging market.
